Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia

PHASE3TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Defibrillators, ImplantableTachycardia, Ventricular
Interventions
PROCEDURE

Ablation

Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization

DRUG

Amiodarone

Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study

Trial Locations (11)

19104

Hospital of the University of Pennsylvania, Philadelphia

22908

University of Virginia Health System, Charlottesville

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

78705

Texas Cardiac Arrhythmia Research Foundation, Austin

100037

Beijng Fuwai Heart Hospital, Beijing

L8L 2X2

Hamilton Health Sciences, Hamilton

L3Y 2P9

Southlake Regional Health Centre, Newmarket

K1Y 4W7

University of Ottawa Heart Institute, Ottawa

H3G 1A4

McGill University Health Center, Montreal

G1V 4G5

Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec

All Listed Sponsors
collaborator

Abbott Medical Devices

INDUSTRY

collaborator

Hamilton Health Sciences Corporation

OTHER

lead

Population Health Research Institute

OTHER